Nov 18 2015
Med Data Quest (MDQ), a pioneering medical informatics total solution provider, today celebrates its successful collaboration with the Oncology Business Unit of the CRO giant WuXi AppTec, delivering the world's first mobile App OncoWuXi that was launched in October for customers to access WuXi oncology tumor models and capabilities more quickly and easily for cancer drug discovery and translational research. This marks MDQ's effective expansion of its business scope into pharmaco-geonomics and cancer research field, leveraging data-mining, statistical computing and information technologies.
The San Diego-based start-up company enters the medical informatics industry with a mission to realize personalized medicine with interdisciplinary methods. MDQ first improves disease diagnosis process and accuracy through collaboration with a major healthcare organization in Southern California, and developed machine learning and natural language processing tools to improve the quality of health care and clinical decision-making. Its recently established partnership with WuXi centers on facilitating the development of cancer treatment drugs by combining comprehensive oncology and omics data. The information service is designed to rapidly curate, process and translate raw pharmaco-geonomics data into actionable information, and the frontend webpage and Apps (iOS and Android) provide domain experts with smooth UI, interactive visualizations, and ease of data access to facilitate data interpretation and knowledge extraction.
"The collaboration with MDQ is highly effective and professional," said Qun-Sheng Ji, Vice President and Head of Oncology Business Unit at WuXi AppTec. "The portable and interactive data platform incorporates encompassing information of more than 1,000 cancer patient-derived xenograft (PDX), human cancer cell-derived xenograft (CDX), and syngeneic mouse tumor models. The massive and complicated raw data is swiftly transformed into easy-to-interpret representations accessible from webpage and Apps, thus helps WuXi to offer the users an open, one-stop, and integrated total solution while facilitating cancer research and drug development."
"We are excited to be part of WuXi's global network and take a small step forward towards precision medicine," said Dr. Yuan Gao, President and CEO of MDQ and former Professor at Johns Hopkins University."Through collaborations with industry leaders, MDQ has established itself as a trustworthy partner with interdisciplinary domain knowledge and innovative solutions. With the industry-acclaimed experience and proven results in both clinical medical treatment and pharmaco-genomics field, MDQ is confident to soon develop other cutting-edge services that will advance personalized medicine."
Unexpected immunotherapy success in rare pancreatic cancer